<DOC>
	<DOCNO>NCT02673697</DOCNO>
	<brief_summary>Prospective , randomize , stratify non blind multi-center , international , post market trial assess non-inferiority study . A minimum 1234 subject enrol approximately 60 worldwide investigational site device commercially available . The primary objective trial test safety efficacy Perceval versus standard suture stented bioprosthetic aortic valve among intended trial population .</brief_summary>
	<brief_title>Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement</brief_title>
	<detailed_description>PERSIST-AVR design collect data sutureless valve ( Perceval sutureless aortic heart valve ) , new type biological aortic valve , compare data standard biological aortic valve , consider gold standard aortic valve replacement . This prospective , randomized international multicenter study plan demonstrate , primary endpoint , non inferiority Major Adverse Cardiac Cerebrovascular ( MACCE ) event one year show superiority resource consumption hospital discharge patient treat Perceval valve compare standard aortic valve replacement . The study plan cover lack prospective , randomized comparison data sutureless valve standard aortic biological suture valve . To achieve primary endpoint , 1234 patient recruit 60 worldwide investigational site . The part trial , investigational site demonstrate experience implantation Perceval able implement requirement study protocol.. All subject severe symptomatic aortic stenosis steno-insufficiency candidate surgical replacement native aortic valve accord establish guideline current medical practice specify Perceval valve Instruction Use ( IFU ) intend population inclusion randomize trial . The patient follow 5 year implant , total duration study include enrollment time 7 year</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>1 . The subject indication treatment valve replacement bioprosthesis accord IFU , either full sternotomy ministernotomy . 2 . The subject aortic valve disease treat commercially available Perceval valve size , base preoperative CTscan . 3 . The subject : 1. critical aortic valve area define initial aortic valve area â‰¤1.0 cm2 aortic valve area index &lt; 0.6 cm2/m2 AND 2 . Mean gradient &gt; 40 mmHg Vmax &gt; 4 m/sec rest echocardiogram simultaneous pressure recording cardiac catheterization [ dobutamine stress , subject leave ventricular ejection fraction ( LVEF ) &lt; 55 % ] velocity ratio &lt; 0.25 ; 4 . The subject symptomatic due aortic stenosis functional class New York Heart Association ( NYHA ) II high . 5 . The subject sign informed consent . 6 . The subject legal minimum age . 7 . The subject available postoperative followup beyond one year . 1 . The subject contraindication treatment Perceval valve bioprosthetic aortic valve state IFU . 2 . The subject aneurismal dilation dissection ascend aortic wall . 3 . The subject schedule concomitant procedure Coronary Aortic Bypass Graft ( CABG ) , myectomy without aortic annulus enlargement 4 . The subject congenital bicuspid ( i.e . Sievers type 0 ) unicuspid aortic valve . 5 . Anatomical structure suitable Perceval valve : aortic root enlargement , ratio diameter sinotubular junction annulus diameter &gt; 1.3 . 6 . The subject prosthetic heart valve position , include mitral valve repair . 7 . The subject stroke myocardial infarction ( STEMI NSTEMI ) within 30 day prior plan valve implant surgery . 8 . The subject active endocarditis , myocarditis , sepsis . 9 . The subject cardiogenic shock manifest low cardiac output need hemodynamic support . 10 . The subject allergic nickel alloy . 11 . The subject already include another clinical trial could confound result clinical investigation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sutureless valve</keyword>
</DOC>